WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025The sale of an additional $1.8 million of unused New...
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for...
BriaCell’s new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040.BriaCell...
LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer...
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is...
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by...
Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global...
If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most aggressive type...
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UKBioNTech...
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...
Houston, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc. “Invectys”, a clinical-stage immunotherapy company headquartered in Houston and dedicated...
SIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel...
NORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indicationsWALTHAM, Mass., Jan. 04,...
CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy targetSAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc....
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage...
Nes-Ziona, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR...